Sugi Predict

Sugi Predict / Compounds / SCHEMBL2545400

SCHEMBL2545400

SCHEMBL2545400

CC(C)(C)OC(=O)N1CCC(N2CCNC2=O)CC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ THRB P10828 1/20 0.50
▸ TP53 P04637 1/20 0.49
▸ GPR119 Q8TDV5 5/20 0.47
▸ HPGD P15428 1/20 0.47
▸ FPR2 P25090 1/20 0.46
▸ RECQL P46063 1/20 0.45
▸ EPHX1 P07099 1/20 0.45
▸ HCAR1 Q9BXC0 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ PTPN2 P17706 1/20 0.44
▸ PTPN1 P18031 1/20 0.44
▸ PTPN6 P29350 1/20 0.44
▸ DDB1 Q16531 1/20 0.43
▸ CRBN Q96SW2 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17977217 0.92 KDM4E (0.48) KDM4EMAPTTHRBTP53GPR119
SCHEMBL18124095 0.92 KDM4E (0.48) KDM4EMAPTTHRBTP53GPR119
SCHEMBL2548432 0.92 KDM4E (0.48) KDM4EMAPTTHRBTP53GPR119
SCHEMBL8667894 0.88 TP53 (0.52) KDM4EMAPTTHRBTP53GPR119
SCHEMBL17582237 0.87 MAPK1 (0.45) KDM4EMAPTTHRBTP53GPR119
SCHEMBL16763447 0.84 FPR2 (0.49) KDM4EMAPTTHRBHPGDFPR2
SCHEMBL16763448 0.84 FPR2 (0.49) KDM4EMAPTTHRBHPGDFPR2
SCHEMBL20986662 0.84 FPR2 (0.49) KDM4EMAPTTHRBHPGDFPR2
SCHEMBL25214672 0.82 KDM4E (0.47) KDM4EMAPTTHRBTP53GPR119
SCHEMBL29586410 0.82 MAPT (0.46) KDM4EMAPTTHRBTP53GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240270762-A1 PENICILLIN-BINDING PROTEIN INHIBITORS SPRING MILL PHARMA, INC. 2024-08-15 — — US disclosed
EP-4347607-A1 PENICILLIN-BINDING PROTEIN INHIBITORS Venatorx Pharmaceuticals, Inc. (US) 2024-04-10 — — EP disclosed
CN-117693511-A Penicillin binding protein inhibitors 维纳拓尔斯制药公司 2024-03-12 — — CN disclosed
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 THERAPEUTICS, INC. (US) 2023-03-16 — — US disclosed
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 — — US disclosed
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos C4 THERAPEUTICS, INC. (US) 2022-08-09 — — US disclosed
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos C4 THERAPEUTICS, INC. (US) 2022-08-09 — — US disclosed
EP-3953332-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 Therapeutics, Inc. (US) 2022-02-16 — — EP disclosed
CN-113677664-A Tricyclic degradants of IKAROS and AIOLOS C4医药公司 2021-11-19 — — CN disclosed
EP-3255993-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2021-01-27 — — EP disclosed
US-20110263559-A1 INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2011-10-27 — — US disclosed
WO-2011133750-A1 INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-10-27 — — WO disclosed
CN-101103020-B Cgrp receptor antagonists MERCK & CO INC 2011-04-27 — — CN disclosed
EP-1856100-B1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2010-05-05 — — EP disclosed
US-7632832-B2 CGRP receptor antagonists MERCK & CO., INC. (US) 2009-12-15 — — US disclosed
EP-1856100-A4 CGRP RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2009-04-15 — — EP disclosed
US-20080125413-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2008-05-29 — — US disclosed
CN-101103020-A CGRP receptor antagonists MERCK & CO INC (US) 2008-01-09 — — CN disclosed
EP-1856100-A2 CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-11-21 — — EP disclosed
WO-2006078554-A2 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos CRBN, IKZF1, IKZF3 KDM4E 315/4885MAPT 1742/4885THRB 2846/4885
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS CRBN, IKZF1, IKZF3 KDM4E 315/4885MAPT 1742/4885THRB 2846/4885
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B KDM4E 2126/4885MAPT 4695/4885THRB 2634/4885
US-20240270762-A1 PENICILLIN-BINDING PROTEIN INHIBITORS PEPD, BPGM, EBPL KDM4E 2087/4885MAPT 3146/4885THRB 1840/4885
US-20080125413-A1 Cgrp Receptor Antagonists CALCRL, NPY1R, CCKBR KDM4E 3342/4885MAPT 2397/4885THRB 432/4885
US-20110263559-A1 INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS KHK, GCK, GCKR KDM4E 374/4885MAPT 3163/4885THRB 2621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.